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ABSTRACT: The potential of dried blood spot (DBS) sampling as an
alternative for classical venous sampling is increasingly recognized, with
multiple applications in, e.g., therapeutic drug monitoring and toxicology.
Although DBS sampling has many advantages, it is associated with several
issues, the hematocrit (Hct) issue being the most widely discussed
challenge, given its possible strong impact on DBS-based quantitation.
Hitherto, no approaches allow Hct prediction from nonvolumetrically
applied DBS. Following a simple and rapid extraction protocol, K+ levels
from 3 mm DBS punches were measured via indirect potentiometry, using
the Roche Cobas 8000 routine chemistry analyzer. The extracts’ K+
concentrations were used to calculate the approximate Hct of the blood
used to generate DBS. A linear calibration line was established, with a Hct
range of 0.19 to 0.63 (lower limit of quantiﬁcation, LLOQ, to upper limit of quantiﬁcation, ULOQ). The procedure was fully
validated; the bias and imprecision of quality controls (QCs) at three Hct levels and at the LLOQ and ULOQ was less than 5 and
12%, respectively. In addition, the inﬂuence of storage (pre- and postextraction), volume spotted, and punch homogeneity was
evaluated. Application on DBS from patient samples (n = 111), followed by Bland and Altman, Passing and Bablok, and Deming
regression analysis, demonstrated a good correlation between the “predicted Hct” and the “actual Hct”. After correcting for the
observed bias, limits of agreement of ±0.049 were established. Incurred sample reanalysis demonstrated assay reproducibility. In
conclusion, potassium levels in extracts from 3 mm DBS punches can be used to get a good prediction of the Hct, one of the
most important “unknowns” in DBS analysis.
Dried blood spot (DBS) sampling is increasingly used as aminimally invasive tool to acquire a representative blood
sample in the context of therapeutic drug monitoring (TDM)
and toxicology.1−4 However, the analysis of DBS is associated
with several issues, such as contamination risk, blood volume
spotted, blood spot homogeneity, and hematocrit (Hct).3−5 Of
these, the Hct is undoubtedly the most widely discussed
challenge, as strongly deviating Hct values may signiﬁcantly
impact DBS-based quantitation.3,5−15 First of all, the Hct
strongly inﬂuences the spreading of a blood drop on ﬁlter
paper, with higher Hct values leading to smaller, more
concentrated spots.3,5−9 Second, the Hct may inﬂuence
parameters such as recovery and matrix eﬀect.6,10 Third,
when DBS results are to be compared with those obtained from
plasma, the distribution of an analyte in red blood cells and
plasma needs to be examined on a case-by-case basis.3,15 These
Hct-associated issues, when compared to conventional plasma
analysis, make DBS-based quantitation suﬀer from an additional
unknown factor of uncertainty.
Several strategies have been proposed to cope with the so-
called “hematocrit eﬀect”.11 The most easy approach is the
analysis of complete, volumetrically applied DBS, obtained by
pipetting or using precision capillaries or other microsampling
devices, delivering a ﬁxed amount of blood to ﬁlter paper.6,10
Indeed, this approach copes with the most evident Hct eﬀect,
i.e., the diﬀerential spreading of blood with varying Hct.
However, volumetric application requires some training and
may be diﬃcult to sustain when DBSs are to be obtained by
patients at home (e.g., in the context of TDM programs). In
these cases, direct application from a cleaned ﬁngertip may be
the best feasible approach. As this implies, per deﬁnition,
nonvolumetric application, DBS punches rather than complete
DBS should be evaluated, necessitating the deﬁnition of a Hct
range and a volume range in which the results for a given
analyte still fulﬁll the acceptance criteria for precision and
accuracy.5,8
Whereas some have considered the correlation between the
DBS diameter and the Hct of volumetrically applied blood,8,16
hitherto, there is no approach available that allows one to trace
back the Hct of DBS obtained by nonvolumetric application of
blood. A “marker” allowing one to trace back the Hct should
fulﬁll several criteria: ﬁrst, it should correlate with the amount
of red blood cells; second, it should be universal (i.e., show
minimal interindividual variation); third, it should be stable
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(i.e., being applicable to both freshly prepared and old DBS, we
found hemoglobin to not fulﬁll this criterion); fourth, its
determination should be possible on a minimal area of the
DBS, while still being easy enough to allow universal
implementation. Keeping these requirements in mind,
potassium (K+) was chosen as a candidate marker to predict
Hct. This electrolyte is primarily located intracellularly, its
intracellular concentration (at approximately 140 mM) being
about 35 times higher than its extracellular concentration.17 In
addition, K+ levels are under tight physiological control, with
normal serum or plasma levels ranging between 3.5 and 5
mM.17 As erythrocytes are the predominant cells in the blood,
roughly outnumbering white blood cells with a factor of 500−
1000, these are the major contributors to the total blood K+
concentration. Hence, the contribution by the serum or plasma
and by other cells accounts for only a low % of the total blood
K+ concentration. As a consequence, physiological changes in
serum or plasma concentration and/or in white blood cell
count are only expected to have a minimal, if any, impact on
total blood K+ concentration. In this report, we describe that K+
measurement in extracts from 3 mm DBS punches, using a
routine clinical chemistry analyzer, allows one to trace back the
Hct of a DBS with acceptable accuracy and precision.
Satisfactory results were obtained after evaluation of the
developed procedure on DBS from patients.
■ EXPERIMENTAL SECTION
Preparation of DBS. Venous blood, used for preparation of
DBS, was obtained from healthy volunteers and collected in
tubes containing Li-heparin as anticoagulant (Venosafe 9 mL
VF-109SHL, Terumo, Leuven, Belgium). DBSs were generated
the same day of blood collection by applying 25 μL of blood
(unless mentioned otherwise) on Whatman 903 ﬁlter paper
(WHA10334885, GE Healthcare, Dassel, Germany), followed
by air drying for a minimum of 2 h. Blood with diﬀerent Hct
was prepared by centrifuging an aliquot of the blood in 2 mL
safe-lock tubes in an Eppendorf 5804R centrifuge (Hamburg,
Germany) for 5 min at 1000g and by removing or adding
plasma. The obtained Hct was measured at all instances in
duplicate using a Sysmex XE-5000 hematology analyzer
(Sysmex Corporation, Kobe, Japan); the mean of these
duplicate measurements was considered as the actual Hct.
For comparing the Hct of Li-heparin blood and ethyl-
enediaminetetraacetic acid (EDTA)(K2) blood, coupled
samples were obtained from both patients and healthy
volunteers. Both groups received information and signed
informed consent before entry into this study, which was
approved by the Ethics Committee of Ghent University
Hospital (project number 2012/314). Harris cutting mats and
micropunchers (Uni-Core, 3.00 mm diameter) were obtained
from Sigma-Alrich (Bornem, Belgium).
Extraction of Potassium from DBS. Evaluation of the
optimal conditions to extract K+ from DBS was done using 3
mm punches from 2 day old and freshly prepared DBS.
Diﬀerent elution solvents were tested: ultrapure water with or
without Triton X-100 (0.45%), PBS, and hypotonic (1:10) PBS
with or without Tween 20 (0.05%). We opted to use solvents
readily containing 2.5 mM KCl, as the ﬁnal K+ concentrations
of the resulting solutions were within the validated range of the
chemistry analyzer (see below), even at the extreme Hct of 0.19
and 0.63. Two subsequent extractions were performed at room
temperature in a 2 mL tube by adding 70 and 30 μL,
respectively, to the DBS punch and shaking for 15 min at 1400
rpm on an Eppendorf Comfort Thermomixer. After spinning
down the punch, the resulting supernatants were transferred to
microcups (Sample Cup Micro 13/16, Roche Diagnostics,
Mannheim, Germany). The results obtained for the DBS were
corrected for those obtained for the extraction buﬀer. In line
with the ﬁndings by Langer et al.,18 we did not ﬁnd a
measurable contribution from blank paper. Comparison of the
diﬀerent elution solvents (4−6 replicates for each solvent; 3
independent experiments) revealed that none outperformed
elution with a 2.5 mM KCl solution in ultrapure water
(Supplementary Figure S-1A, Supporting Information). Using
2.5 mM KCl in ultrapure water, the optimal extraction
conditions were evaluated further (4−6 replicates for each
condition). This revealed that (i) two subsequent elutions with
50 μL equaled elution with 70 and 30 μL respectively, and was
better than a single elution with 100 μL; (ii) maximal extraction
was already obtained within 1 min of shaking at 1400 rpm; (iii)
extraction at 37 °C did not improve the extraction eﬃciency
(Supplementary Figure S-1B, Supporting Information).
Analyses. Routine Hct and K+ measurements were
performed in the ISO 15189 accredited Laboratory of Clinical
Biology at Ghent University Hospital. Hct determinations were
performed using a Sysmex XE-5000 hematology analyzer,
having a measurement range of 0.17 (arbitrarily set, i.e., the
lowest quality control (QC) applied in the routine laboratory)
to 0.75. K+ measurements were performed by indirect
potentiometry using an ion-selective electrode (ISE) using
the ISE module of the Roche Cobas 8000 chemistry analyzer
(Roche Diagnostics), disposing of two measurement units and
having technical limits of 1.5 and 10 mM. The validation data of
both clinical Hct and K+ determinations on these analyzers can
be found in the Supporting Information. For the validation and
application, K+ and Hct measurements were performed in
duplicate (unless otherwise mentioned) and the average of
these duplicates was used for the calculations.
Validation. Homoscedasticity (homogeneity of variances),
linearity, and the choice of the calibration model were evaluated
by generating ﬁve 7-point calibration curves from DBS,
prepared from blood with a Hct of ±0.25, 0.30, 0.39, 0.45,
0.50, 0.55, and 0.61 (prepared from a single donor).
Homoscedasticity was examined by plotting the absolute
residuals versus the Hct and by performing the F-test at the
lowest and highest calibrator levels, at the 99% conﬁdence
interval (CI).19,20 Linearity was assessed by performing Fisher’s
test.21 Calibration curves were generated by unweighted, 1/x,
1/x2, 1/y, and 1/y2 weighted linear regression. The choice of
the calibration model was based upon the sum % relative error
(RE) and the % RE plot versus Hct.19
For the evaluation of accuracy (% bias) and precision (%
RSD, relative standard deviation), we prepared on each of 4
diﬀerent days, two 7-point calibration curves from blood with a
Hct of ±0.19, 0.26, 0.33, 0.42, 0.48, 0.55, and 0.63. In
conjunction with every calibration line, three DBS QCs (with a
Hct of ±0.24, 0.41, and 0.58, further referred to as low,
medium, and high QC) were prepared. For details we refer to
the Supporting Information.
The impact of the punching site and of the applied volume
was evaluated at the three Hct QC levels. K+ concentrations
obtained from central punches were compared with those
obtained from peripheral punches, excluding the very edge (n =
6). The impact of the volume applied was evaluated in DBS
prepared by spotting 15, 17.5, 20, 25, 30, 35, 40, or 50 μL of
blood (n = 6).
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The inﬂuence of storage was evaluated both before and after
extraction of DBS. Postextraction stability of the K+
concentrations was evaluated by combining the extracts of 3
punches in 1 microcup (n = 6), followed by direct evaluation
and after 1, 6, 17, 24, 42, and 72 h. The inﬂuence of storage on
K+ in DBS was evaluated by comparing the K+ concentrations
from freshly prepared DBS (dried for 2 h) with those from
DBS, stored at room temperature for 1 or 55 days and stored at
60 °C for 20 h.
Finally, we performed incurred sample reanalysis (with 7
days in between) on a subset (n = 49) of patient DBSs (see
below). More than 2/3 of the repeated measurements should
fulﬁll the acceptance criterion, i.e., lie within the limits of ±20%
of the mean of the original and the corresponding reanalysis
result.22
Application to Patient Samples. Evaluation of the
procedure was performed using blood samples destined for
routine clinical chemistry and hematology analysis, collected in
Li-heparin tubes (Venosafe 2 mL VF-052SHL, 6 mL VF-
106SAHL, or 9 mL VF-109SHL) and in 4 mL EDTA(K2) tubes
(Venosafe VF-054SDK) (all from Terumo, Leuven, Belgium).
DBSs were prepared upon arrival at the clinical laboratory by
pipetting 25 μL of Li-heparin-anticoagulated blood onto ﬁlter
paper (n = 118). Relevant routine clinical parameters evaluated
in the plasma obtained from these tubes included hemolytic
index and plasma K+ concentration. Hct from corresponding
EDTA(K2) tubes was determined via a single measurement on
the Sysmex XE-5000. Following extraction from one 3 mm
DBS punch per patient, K+ levels were measured in duplicate.
Samples with evidence of (or no data on) hemolysis (hemolytic
index above 88) (n = 2) and samples where no duplicate results
of extracted K+ were obtained (n = 5) were excluded, resulting
in a ﬁnal data set of 111 samples.
Data Analysis. Statistical evaluation of the data was carried
out using IBM SPSS Statistics 19 and Microsoft Excel 2010.
Comparisons between the diﬀerent extraction conditions were
made using unifactorial ANOVA analysis. An unpaired t test (α
= 0.05; 95% CI) was used to evaluate the inﬂuence of storage
pre- and postextraction and to evaluate the eﬀect of site of
punching and applied volume.
Microsoft Excel 2010 was used to generate a Bland and
Altman plot, while Medcalc software version 12.3.0.0 (http://
www.medcalc.org) was used for Passing and Bablok and
Deming linear regression analysis, for generating boxplots, and
for generation of a mountain plot, depicting the distribution of
the diﬀerences between the compared methods. The % RSDs,
necessary for performing Deming linear regression analysis,
corresponded to 0.81% for the Sysmex-measured Hct (i.e., the
% RSD for the highest QC) and were derived from the
duplicates (calculated from duplicate K+ measurements) for the
calculated Hct.
Figure 1. Inﬂuence of storage of extracts on the K+ concentration in the extracts. The mean K+ concentration at the diﬀerent time points is shown,
together with the standard deviation (n = 6) (A). Inﬂuence of the punch localization on K+ concentration in the extracts, at three diﬀerent Hct levels.
The bars show the mean K+ concentration, together with the standard deviation (n = 6) (B). Inﬂuence of the volume used to generate DBS on the
K+ concentration in DBS extracts, at three Hct levels. The bars show the mean of 3 independent experiments (each with n = 6 for every volume),
with indication of the pooled standard deviation. A 25 μL DBS was taken as the reference (C). Inﬂuence of long-term storage (up to 55 days) at
ambient temperature or short-term storage (20 h) at elevated temperature (60 °C) on K+ concentrations in DBS. The bars show the mean and
standard deviation (n = 6) (D).
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■ RESULTS AND DISCUSSION
Optimization of the extraction of K+ from 3 mm DBS punches
resulted in the following optimal extraction conditions: two
subsequent 5 min extractions at room temperature, under
continuous shaking (1400 rpm), using 50 μL of a 2.5 mM KCl
solution in ultrapure water. After the ﬁrst extraction, 40 μL was
transferred to a microcup; after the second extraction, another
50 μL extract was added to the microcup. Although a 1 min
extraction gave equivalent results (Supplementary Figure S-1B,
Supporting Information), we opted in the ﬁnal protocol for a 5
min extraction for practical reasons. The combined extracts can
be stored in the microcups at 4 °C for at least 72 h (Figure 1A)
before analysis by the routine clinical chemistry analyzer. The
developed procedure is easy and straightforward and is in
principle fully automatable, allowing high-throughput analyses.
Several parameters have been shown to potentially inﬂuence
the distribution of analytes in DBS. Therefore, it is important to
control whether the K+ concentration measured in the 3 mm
DBS punches is aﬀected by the punch location (peripheral
versus central) or by the blood volume that was applied to
prepare the DBS. Irrespective of the Hct, no signiﬁcant
diﬀerence (95% CI) was seen between the K+ concentrations in
discs punched out from 25 μL DBS peripherally versus centrally
(Figure 1B). Evaluation of the applied volume revealed that
diﬀerences in K+ concentrations never exceeded 15%, taking 25
μL DBS as the reference and as extreme volumes 15 and 50 μL,
respectively, irrespective of the Hct. However, although limited
in extent, we did observe a trend of increasing K+
concentrations upon increasing DBS volume (Figure 1C), as
also others did, albeit for other analytes.5,9 To minimize this
volume eﬀect, we propose that a volume criterion is set using
ﬁlter paper with two preprinted concentric circles, in which a
DBS should ﬁll the inner circle (8 mm diameter) completely,
while not exceeding the outer circle (13 mm diameter). Doing
so, the volume of DBS will always lie between approximately
20−25 and 40−50 μL, whatever the Hct (Supplementary
Figure S-2, Supporting Information). In our experience, this
volume range covers the typical volumes obtained from a single
drop of blood following a ﬁngerprick.
Statistical evaluation of the calibration data revealed that the
data were homoscedastic (i.e., had homogeneous variances)
and that the calibration lines were linear, with no need for
weighting. The slope and intercept of the calibration curve were
3.15 and −0.09, respectively, with respective 95% CI of 2.96−
3.34 and −0.20 to −0.05. The lower limit of quantiﬁcation
(LLOQ) and upper limit of quantiﬁcation (ULOQ) were
arbitrarily set at the lowest (0.19) and highest (0.63) points of
the mean calibration curve, respectively. Even in a hospital
setting, with an obvious overrepresentation of critically ill
patients, this Hct range of 0.19−0.63 covers over 99.5% of the
patients (1-year data, Ghent University Hospital). As shown in
Table 1, precision and accuracy for the QCs (3 levels), LLOQ,
and ULOQ fulﬁlled the predeﬁned acceptance criteria at all
instances (<15% RSD and bias). To conﬁrm the validity of our
approach, this part of the validation was duplicated, using blood
from another donor, giving similar results (Supplementary
Table S-1, Supporting Information). Moreover, when the QCs
from this second donor were ﬁtted into the ﬁnal regression
equation, obtained using blood from the ﬁrst donor (and vice
versa), precision and accuracy acceptance criteria were still met
(Table 1 and Supplementary Table S-1, Supporting Informa-
tion). Furthermore, evaluation of the inﬂuence of storage
indicated that no signiﬁcant change in K+ concentration
occurred upon prolonged storage of DBS at room temperature
or after storage for 20 h at 60 °C (Figure 1D).
The developed procedure was evaluated using paired
EDTA(K2) and Li-heparin blood samples, collected from
patients (n = 111) for routine clinical purposes. These were
used for direct Hct determination and for generating DBS,
respectively. For the latter, the developed procedure was
applied to calculate the Hct. Figure 2A shows the Bland and
Altman comparison of the actually measured Hct and the
calculated Hct, with indication of the mean diﬀerence and the
limits of agreements (LoAs), all with their 95% CI. A ﬁrst
conclusion, which can be inferred from this comparison, is that
there is a negative bias of 0.019. As suggested by Bland and
Altman, when a consistent bias is observed between two
methods (a reference method and a new method), this bias can
be adjusted in the new method.23 We opted to do this for three
reasons. First, the slightly negative bias was consistently
observed: when splitting the total data set of 111 patients
into three subdata sets (each analyzed on a diﬀerent day), a
negative bias was observed for all subdata sets (Supplementary
Figure S-3, Supporting Information). Second, a trend line
through all data points of the Bland and Altman comparison
had a slope close to zero, demonstrating the absence of a
proportional diﬀerence (i.e., the bias does not depend on the
Hct) (data not shown). Third, at least part of this bias can be
explained by the fact that Hct values obtained from Li-heparin
blood, used for setting up the calibration lines and for
generating the DBS, are signiﬁcantly lower than the Hct values
obtained from the “gold standard” for Hct measurement, i.e.,
EDTA(K2) blood. We made this observation in paired blood
samples of both patients and healthy volunteers and found it to
be related to the mean corpuscular volume of the red blood
cells, which is signiﬁcantly lower in Li-heparin blood (data not
shown). Figure 2B shows a mountain plot, depicting the
distribution of the diﬀerences between both methods for all
data points, after bias correction. This plot nicely demonstrates
that the diﬀerences are centered around zero. Passing and
Bablok linear regression analysis was performed, also after
correcting for the bias (Figure 2C, Table 2). A linear model ﬁts
Table 1. Overview of the Data for Accuracy and Inter- and
Intrabatch (n = 8 Duplicate Measurements) Precision for
Donor 1a
accuracy
(% bias)
intrabatch
precision
(% RSD)
interbatch
precision
(% RSD)
A
QC low −1.07 8.49 11.69
QC medium 0.09 3.30 5.05
QC high −2.25 3.42 6.72
B
LLOQ (0.19) 4.20 9.25 9.25
ULOQ (0.63) 2.75 4.76 9.17
C
QC low (donor 2) −2.05 8.75 10.57
QC medium (donor 2) 0.57 3.37 6.26
QC high (donor 2) −1.31 3.54 6.61
aA and B, respectively, give the data obtained for QCs (3 Hct levels)
and LOQs (LLOQ and ULOQ), prepared from blood from the same
donor as the one in which the calibrators were prepared. C gives the
data for QCs prepared from blood from another donor than the one in
which the calibrators were prepared.
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the data, and the 95% CI of the intercept contains the zero
value. Hence, after correction for the bias, there is no systematic
diﬀerence between the two methods. In addition, as the 95% CI
for the slope contains the value of 1, there is no proportional
diﬀerence between the two methods. The same conclusions
were obtained when performing Deming regression analysis
(Figure 2D, Table 2). A second conclusion that can be drawn
from the Bland and Altman comparison is that the LoAs, after
correcting for the bias, lie at ±0.049. These LoAs are
acceptable, given the purpose of the method, i.e., getting an
approximate estimation of the original Hct. As such, the
developed procedure allows one to make a statement whether
results obtained with a certain analytical method are indeed
valid (i.e., whether the Hct of any given DBS lies within the
predeﬁned range of a validated method) or rather provide an
under- or overestimation of the actual analyte concentration.
The variation of the K+-measurements themselves (i.e.,
technical variation) accounts for less than 0.01 of the observed
LoAs. Although this is overall limited, it may be worthwhile to
evaluate whether the use of alternative methodologies for K+
measurement, such as ﬂame photometry, atomic absorption, or
inductively coupled plasma-based methods, may further
improve the LoAs. However, the possible beneﬁt in increased
sensitivity and/or precision of alternative conﬁgurations should
be weighed against the advantage of high-throughput and
simplicity oﬀered by fully automated high-speed clinical
analyzers (e.g., the Cobas 8000 conﬁguration used here allows
up to 600 samples/hour to be analyzed for Na+, K+ and Cl−).
The prime responsible factors for the LoAs are the variation
induced by manipulation (manual punching, extraction, and
transfer) and the biological variation. With respect to the
former, it can be expected that the LoAs may be narrowed
further by automation, as in this work all steps of the sample
preparation procedure were performed manually. With respect
to the biological variation, we evaluated whether there was a
possible inﬂuence of the plasma K+ concentration. To this end,
we looked if a correlation could be observed between the
deviation of the calculated Hct from the expected Hct and the
deviation of the plasma K+ concentration (range of 2.8−5.2
mM) from the median plasma K+ concentration (4.0 mM). As
expected, given the minor contribution of the plasma K+
concentration, no such correlation was observed (Supplemen-
tary Figure S-4, Supporting Information).
Incurred sample reanalysis, performed on a subset of the
patient samples (n = 49), demonstrated that, with one single
exception, all repeated measurements lie within ±10% of the
mean of the repeated and the original measurement. Hence, the
Figure 2. Bland and Altman comparison of calculated Hct and measured Hct. The mean diﬀerence, together with the upper and lower LoAs is
indicated, with the respective 95% CI (A). Mountain plot depicting the distribution of the diﬀerences between the calculated and the measured Hct,
after correction for the bias (B). Passing and Bablok (C) and Deming (D) regression analysis of the calculated and measured Hct, after correction for
the bias.
Table 2. Results of the Passing and Bablok and Deming
Linear Regression Analysis of the Comparison of the
Calculated Hct with the Measured Hcta
Passing and Bablok
linear regression
Deming linear
regression
regression equation 1.036x − 0.012 0.938x + 0.019
95% CI slope 0.943 1.141 0.861 1.015
95% CI intercept −0.042 0.018 −0.004 0.042
aThe regression equations are given, together with the 95% CI for the
slope and intercept.
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acceptance criterion (2/3 lying within ±20%) was more than
met, demonstrating good assay reproducibility (Figure 3).22
■ CONCLUSION
In conclusion, the successful validation of the developed
procedure and its application on real patient samples
demonstrate its practical applicability, covering a Hct range of
0.19−0.63. The developed methodology, which because of its
simplicity and speed can be easily introduced into any
automated clinical laboratory, allows one to make a good
prediction of the Hct, one of the most important “unknowns”
in DBS sampling. Every analyst working with DBS is aware of
the Hct eﬀect and, in our opinion, any validated method using
DBS punches should deﬁne a Hct range in which precision and
accuracy for a given analyte are still acceptable. However,
hitherto, there was no methodology available to actually
conﬁrm that the Hct of blood used to generate a given DBS
actually lies within the acceptable range. Being able to predict
the Hct of any given DBS may also render it possible in the
future to cope with, and possibly even to adjust for, the
“hematocrit eﬀect” in any given DBS-based analytical method.
In addition, even though analysis of complete DBS, requiring
volumetric application, has been advocated as one of the best
solutions to overcome the Hct eﬀect,11 still, correct
interpretation of the obtained results, and correlation with
plasma data, requires knowledge of the Hct of the DBS. It will
be important to extend this study in the future to true capillary
blood samples. Importantly, in these cases, capillary Hct should
be determined as a reference, as this may diﬀer from venous
Hct;3,24,25 a ﬁnding we also observed in our preliminary
experiments.
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